Maharashtra FDA Asks To Inspect Units Making Liquid Orals

Mumbai : Maharashtra has ordered a recall of all liquid orals made and offered by Maiden Pharmaceuticals within the state, following a latest controversy over its cough syrups in Gambia. The state’s Food and Drug Administration has additionally directed drug inspectors to study all of the units manufacturing liquid orals in Maharashtra, individuals within the know instructed ET.

“The inspection is primarily to identify if the units have used industrial-grade solvents and not pharma-grade solvents,” he mentioned.

The state has about 250 manufacturing units that make cough syrups. The official mentioned the report must be obtainable by October 31 however given the quite a few units within the state and the pageant season, there may very well be some delay.

According to Maharashtra FDA’s order, all merchandise which aren’t of pharmacopeia-grade expedient requirements must be checked for the presence of different excipients.

It has ordered checks and evaluation and warned that these discovered utilizing industrial-grade expedient would face strict motion. “All of this to be done before October 31,” it mentioned.

In September, the World Health Organization warned that laboratory evaluation of cough syrups manufactured by Maiden Pharmaceuticals confirmed “unacceptable” quantities of diethylene glycol and ethylene glycol, which might be poisonous and lead to acute kidney issues.

Since then, drug authorities in a number of states have swung into motion.

  • Related Posts

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India, a leading healthcare technology company, has expanded its ELUXEO 8000 endoscopy portfolio with the launch of its next-generation therapeutic gastroscopes at Endocon 2026. India is witnessing a growing…

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Amidst years of uncertainty over the regulation of e-pharmacies in the country, the draft Drugs, Medical Devices and Cosmetics Bill, 2026, proposes to bestow the powers with the drugs inspectors…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Fujifilm India launches therapeutic endoscopy portfolio at Endocon 2026

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Draft bill proposes powers for DIs to inspect online pharmacy office premises

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    Argentina committed to reducing barriers to facilitate entry of Indian pharma sector: Government

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    FDA cancels drug sale licences of Cipla Pharma & Life Sciences’ Pune Carry and Forwarding unit

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    Delhi DCA mandates digital tracking for controlled substances on new DMS portal

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?

    How much of Healthcare Research reaches Bedside in India? Or gets Lost in Translation?